Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?
Identifieur interne : 001951 ( Istex/Corpus ); précédent : 001950; suivant : 001952Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?
Auteurs : P. Oxholm ; K. AsmussenSource :
- Medical Hypotheses [ 0306-9877 ] ; 1998.
English descriptors
- Teeft :
- Acta ophthalmol, Arthritis rheum, Autoantibody, Autoimmune, Blood levels, Carbon anhydrase, Clin, Clin rheumatol, Clinical data, Clinical disease manifestations, Clinical manifestations, Clinical status, Clinical trials, Copenhagen county hospital, Cytokine, Diffusion capacity, Disease activity, Disease duration, Disease manifestations, Disease markers, Disease onset, Disease processes, Disease status, Exocrine, Exocrine autoimmunity, Exocrine glands, Exocrine immunoinflammation, Exocrine lymphoproliferation, Exocrine manifestations, Immunological aspects, Immunopathological features, Irreversible organ injuries, Labial, Laboratory markers, Langerhans cells, Literature survey, Longitudinal, Longitudinal analysis, Longitudinal course, Longitudinal studies, Longitudinal study, Lung function, Lymphocyte, Lymphocyte activity, Lymphocyte disease, Lymphocyte products, Lymphoproliferation, Manifestation, Manthorpe, Mast cells, Medical hypotheses, Medical treatment, Moutsopoulos, Nonexocrine, Nonexocrine manifestations, Ocular exocrine disease, Oral pathol, Organ damage, Oxholm, Pathogenesis, Plasma cells, Present data, Primary syndrome, Receptor, Retrospective study, Rheum, Rheumatic diseases, Rheumatoid factors, Rheumatol, Salivary, Salivary glands, Scand, Semin arthritis rheum, Soluble interleukin, Soluble markers, Standardized assessment, Surface exocrine manifestations, Syndrome, Vascular disease, Year period.
Abstract
Abstract: Primary Sjögren's syndrome (pSS) is increasingly acknowledged as a disease entity with consistent pathogenesis and clinical presentation. This has encouraged proposals for uniform nomenclature, as well as for classification of disease subsets and clinical disease manifestations. The purpose of this literature survey is to analyse present pathogenetic and clinical data on pSS from the viewpoint of their usability for developing criteria for activity and damage. It appears that the routinely used tests for evaluating clinical disease manifestations in pSS probably measure both activity and damage. Moreover, no immunopathogenic marker has been shown to adequately represent all aspects of disease activity in pSS. The survey demonstrates the need for longitudinal studies in which potential markers of disease activity and damage are validated.
Url:
DOI: 10.1016/S0306-9877(98)90268-7
Links to Exploration step
ISTEX:1F22ACAE23135D33AFC33247C0574B536E66A427Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title><author><name sortKey="Oxholm, P" sort="Oxholm, P" uniqKey="Oxholm P" first="P." last="Oxholm">P. Oxholm</name><affiliation><mods:affiliation>Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Denmark</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence to: Peter Oxholm, Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark (Fax: +45 39777619</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: droxholmo@inet.uni-c.dk</mods:affiliation></affiliation></author><author><name sortKey="Asmussen, K" sort="Asmussen, K" uniqKey="Asmussen K" first="K." last="Asmussen">K. Asmussen</name><affiliation><mods:affiliation>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1F22ACAE23135D33AFC33247C0574B536E66A427</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0306-9877(98)90268-7</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-XK3BNRK0-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001951</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001951</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title><author><name sortKey="Oxholm, P" sort="Oxholm, P" uniqKey="Oxholm P" first="P." last="Oxholm">P. Oxholm</name><affiliation><mods:affiliation>Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Denmark</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence to: Peter Oxholm, Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark (Fax: +45 39777619</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: droxholmo@inet.uni-c.dk</mods:affiliation></affiliation></author><author><name sortKey="Asmussen, K" sort="Asmussen, K" uniqKey="Asmussen K" first="K." last="Asmussen">K. Asmussen</name><affiliation><mods:affiliation>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Medical Hypotheses</title><title level="j" type="abbrev">YMEHY</title><idno type="ISSN">0306-9877</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">50</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="483">483</biblScope><biblScope unit="page" to="492">492</biblScope></imprint><idno type="ISSN">0306-9877</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0306-9877</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acta ophthalmol</term><term>Arthritis rheum</term><term>Autoantibody</term><term>Autoimmune</term><term>Blood levels</term><term>Carbon anhydrase</term><term>Clin</term><term>Clin rheumatol</term><term>Clinical data</term><term>Clinical disease manifestations</term><term>Clinical manifestations</term><term>Clinical status</term><term>Clinical trials</term><term>Copenhagen county hospital</term><term>Cytokine</term><term>Diffusion capacity</term><term>Disease activity</term><term>Disease duration</term><term>Disease manifestations</term><term>Disease markers</term><term>Disease onset</term><term>Disease processes</term><term>Disease status</term><term>Exocrine</term><term>Exocrine autoimmunity</term><term>Exocrine glands</term><term>Exocrine immunoinflammation</term><term>Exocrine lymphoproliferation</term><term>Exocrine manifestations</term><term>Immunological aspects</term><term>Immunopathological features</term><term>Irreversible organ injuries</term><term>Labial</term><term>Laboratory markers</term><term>Langerhans cells</term><term>Literature survey</term><term>Longitudinal</term><term>Longitudinal analysis</term><term>Longitudinal course</term><term>Longitudinal studies</term><term>Longitudinal study</term><term>Lung function</term><term>Lymphocyte</term><term>Lymphocyte activity</term><term>Lymphocyte disease</term><term>Lymphocyte products</term><term>Lymphoproliferation</term><term>Manifestation</term><term>Manthorpe</term><term>Mast cells</term><term>Medical hypotheses</term><term>Medical treatment</term><term>Moutsopoulos</term><term>Nonexocrine</term><term>Nonexocrine manifestations</term><term>Ocular exocrine disease</term><term>Oral pathol</term><term>Organ damage</term><term>Oxholm</term><term>Pathogenesis</term><term>Plasma cells</term><term>Present data</term><term>Primary syndrome</term><term>Receptor</term><term>Retrospective study</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid factors</term><term>Rheumatol</term><term>Salivary</term><term>Salivary glands</term><term>Scand</term><term>Semin arthritis rheum</term><term>Soluble interleukin</term><term>Soluble markers</term><term>Standardized assessment</term><term>Surface exocrine manifestations</term><term>Syndrome</term><term>Vascular disease</term><term>Year period</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Primary Sjögren's syndrome (pSS) is increasingly acknowledged as a disease entity with consistent pathogenesis and clinical presentation. This has encouraged proposals for uniform nomenclature, as well as for classification of disease subsets and clinical disease manifestations. The purpose of this literature survey is to analyse present pathogenetic and clinical data on pSS from the viewpoint of their usability for developing criteria for activity and damage. It appears that the routinely used tests for evaluating clinical disease manifestations in pSS probably measure both activity and damage. Moreover, no immunopathogenic marker has been shown to adequately represent all aspects of disease activity in pSS. The survey demonstrates the need for longitudinal studies in which potential markers of disease activity and damage are validated.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>primary syndrome</json:string><json:string>exocrine</json:string><json:string>rheumatol</json:string><json:string>disease activity</json:string><json:string>lymphocyte</json:string><json:string>oxholm</json:string><json:string>clin</json:string><json:string>syndrome</json:string><json:string>moutsopoulos</json:string><json:string>labial</json:string><json:string>cytokine</json:string><json:string>manthorpe</json:string><json:string>lymphoproliferation</json:string><json:string>rheum</json:string><json:string>scand</json:string><json:string>arthritis rheum</json:string><json:string>disease status</json:string><json:string>receptor</json:string><json:string>nonexocrine</json:string><json:string>autoantibody</json:string><json:string>autoimmune</json:string><json:string>organ damage</json:string><json:string>clinical disease manifestations</json:string><json:string>salivary</json:string><json:string>longitudinal</json:string><json:string>disease duration</json:string><json:string>disease manifestations</json:string><json:string>clin rheumatol</json:string><json:string>salivary glands</json:string><json:string>blood levels</json:string><json:string>exocrine lymphoproliferation</json:string><json:string>plasma cells</json:string><json:string>laboratory markers</json:string><json:string>pathogenesis</json:string><json:string>longitudinal study</json:string><json:string>clinical status</json:string><json:string>semin arthritis rheum</json:string><json:string>medical hypotheses</json:string><json:string>exocrine immunoinflammation</json:string><json:string>literature survey</json:string><json:string>year period</json:string><json:string>exocrine glands</json:string><json:string>disease processes</json:string><json:string>lymphocyte products</json:string><json:string>retrospective study</json:string><json:string>manifestation</json:string><json:string>clinical trials</json:string><json:string>rheumatoid factors</json:string><json:string>mast cells</json:string><json:string>langerhans cells</json:string><json:string>soluble markers</json:string><json:string>longitudinal course</json:string><json:string>nonexocrine manifestations</json:string><json:string>vascular disease</json:string><json:string>surface exocrine manifestations</json:string><json:string>ocular exocrine disease</json:string><json:string>carbon anhydrase</json:string><json:string>exocrine autoimmunity</json:string><json:string>disease markers</json:string><json:string>diffusion capacity</json:string><json:string>lymphocyte disease</json:string><json:string>present data</json:string><json:string>standardized assessment</json:string><json:string>rheumatic diseases</json:string><json:string>exocrine manifestations</json:string><json:string>clinical manifestations</json:string><json:string>irreversible organ injuries</json:string><json:string>medical treatment</json:string><json:string>disease onset</json:string><json:string>longitudinal studies</json:string><json:string>clinical data</json:string><json:string>lymphocyte activity</json:string><json:string>immunopathological features</json:string><json:string>immunological aspects</json:string><json:string>copenhagen county hospital</json:string><json:string>oral pathol</json:string><json:string>longitudinal analysis</json:string><json:string>soluble interleukin</json:string><json:string>acta ophthalmol</json:string><json:string>lung function</json:string></teeft></keywords><author><json:item><name>P. Oxholm</name><affiliations><json:string>Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Denmark</json:string><json:string>Correspondence to: Peter Oxholm, Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark (Fax: +45 39777619</json:string><json:string>E-mail: droxholmo@inet.uni-c.dk</json:string></affiliations></json:item><json:item><name>K. Asmussen</name><affiliations><json:string>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-XK3BNRK0-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Primary Sjögren's syndrome (pSS) is increasingly acknowledged as a disease entity with consistent pathogenesis and clinical presentation. This has encouraged proposals for uniform nomenclature, as well as for classification of disease subsets and clinical disease manifestations. The purpose of this literature survey is to analyse present pathogenetic and clinical data on pSS from the viewpoint of their usability for developing criteria for activity and damage. It appears that the routinely used tests for evaluating clinical disease manifestations in pSS probably measure both activity and damage. Moreover, no immunopathogenic marker has been shown to adequately represent all aspects of disease activity in pSS. The survey demonstrates the need for longitudinal studies in which potential markers of disease activity and damage are validated.</abstract><qualityIndicators><score>8.464</score><pdfWordCount>5130</pdfWordCount><pdfCharCount>33693</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>540 x 713 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>122</abstractWordCount><abstractCharCount>859</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title><pmid><json:string>9710321</json:string></pmid><pii><json:string>S0306-9877(98)90268-7</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>1994</title><language><json:string>unknown</json:string></language><pages><first>569</first><last>570</last></pages></serie><host><title>Medical Hypotheses</title><language><json:string>unknown</json:string></language><publicationDate>1998</publicationDate><issn><json:string>0306-9877</json:string></issn><pii><json:string>S0306-9877(00)X0315-5</json:string></pii><volume>50</volume><issue>6</issue><pages><first>483</first><last>492</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1998</json:string></date><geogName></geogName><orgName><json:string>Department of Rheumatology U, Copenhagen County Hospital</json:string><json:string>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Niels Andersens</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl><json:string>Pavlidis et al</json:string><json:string>Kruize et al</json:string><json:string>Mialon et al</json:string><json:string>Ichikawa et al</json:string><json:string>Jonsson et al</json:string><json:string>Kelly et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-XK3BNRK0-3</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - neurology & neurosurgery</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1016/S0306-9877(98)90268-7</json:string></doi><id>1F22ACAE23135D33AFC33247C0574B536E66A427</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-XK3BNRK0-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-XK3BNRK0-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-XK3BNRK0-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1998</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title><author xml:id="author-0000"><persName><forename type="first">P.</forename><surname>Oxholm</surname></persName><email>droxholmo@inet.uni-c.dk</email><affiliation>Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Denmark</affiliation><affiliation>Correspondence to: Peter Oxholm, Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark (Fax: +45 39777619</affiliation></author><author xml:id="author-0001"><persName><forename type="first">K.</forename><surname>Asmussen</surname></persName><affiliation>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</affiliation></author><idno type="istex">1F22ACAE23135D33AFC33247C0574B536E66A427</idno><idno type="ark">ark:/67375/6H6-XK3BNRK0-3</idno><idno type="DOI">10.1016/S0306-9877(98)90268-7</idno><idno type="PII">S0306-9877(98)90268-7</idno></analytic><monogr><title level="j">Medical Hypotheses</title><title level="j" type="abbrev">YMEHY</title><idno type="pISSN">0306-9877</idno><idno type="PII">S0306-9877(00)X0315-5</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998"></date><biblScope unit="volume">50</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="483">483</biblScope><biblScope unit="page" to="492">492</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Primary Sjögren's syndrome (pSS) is increasingly acknowledged as a disease entity with consistent pathogenesis and clinical presentation. This has encouraged proposals for uniform nomenclature, as well as for classification of disease subsets and clinical disease manifestations. The purpose of this literature survey is to analyse present pathogenetic and clinical data on pSS from the viewpoint of their usability for developing criteria for activity and damage. It appears that the routinely used tests for evaluating clinical disease manifestations in pSS probably measure both activity and damage. Moreover, no immunopathogenic marker has been shown to adequately represent all aspects of disease activity in pSS. The survey demonstrates the need for longitudinal studies in which potential markers of disease activity and damage are validated.</p></abstract></profileDesc><revisionDesc><change when="1998">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-XK3BNRK0-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>YMEHY</jid><aid>98902687</aid><ce:pii>S0306-9877(98)90268-7</ce:pii><ce:doi>10.1016/S0306-9877(98)90268-7</ce:doi><ce:copyright type="unknown" year="1998"></ce:copyright></item-info><head><ce:title>Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</ce:title><ce:author-group><ce:author><ce:given-name>P.</ce:given-name><ce:surname>Oxholm</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="COR1"><ce:sup>1</ce:sup></ce:cross-ref><ce:e-address>droxholmo@inet.uni-c.dk</ce:e-address></ce:author><ce:author><ce:given-name>K.</ce:given-name><ce:surname>Asmussen</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Denmark</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>∗</ce:label><ce:textfn>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>1</ce:label><ce:text>Correspondence to: Peter Oxholm, Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark (Fax: +45 39777619</ce:text></ce:correspondence></ce:author-group><ce:date-received day="24" month="2" year="1997"></ce:date-received><ce:date-accepted day="3" month="4" year="1997"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Primary Sjögren's syndrome (pSS) is increasingly acknowledged as a disease entity with consistent pathogenesis and clinical presentation. This has encouraged proposals for uniform nomenclature, as well as for classification of disease subsets and clinical disease manifestations. The purpose of this literature survey is to analyse present pathogenetic and clinical data on pSS from the viewpoint of their usability for developing criteria for activity and damage. It appears that the routinely used tests for evaluating clinical disease manifestations in pSS probably measure both activity and damage. Moreover, no immunopathogenic marker has been shown to adequately represent all aspects of disease activity in pSS. The survey demonstrates the need for longitudinal studies in which potential markers of disease activity and damage are validated.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?</title></titleInfo><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Oxholm</namePart><affiliation>Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Denmark</affiliation><affiliation>Correspondence to: Peter Oxholm, Department of Rheumatology U, Copenhagen County Hospital in Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark (Fax: +45 39777619</affiliation><affiliation>E-mail: droxholmo@inet.uni-c.dk</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Asmussen</namePart><affiliation>Department of Medicine TA Rigshospitalet, National University Hospital, Copenhagen, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1998</dateIssued><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Primary Sjögren's syndrome (pSS) is increasingly acknowledged as a disease entity with consistent pathogenesis and clinical presentation. This has encouraged proposals for uniform nomenclature, as well as for classification of disease subsets and clinical disease manifestations. The purpose of this literature survey is to analyse present pathogenetic and clinical data on pSS from the viewpoint of their usability for developing criteria for activity and damage. It appears that the routinely used tests for evaluating clinical disease manifestations in pSS probably measure both activity and damage. Moreover, no immunopathogenic marker has been shown to adequately represent all aspects of disease activity in pSS. The survey demonstrates the need for longitudinal studies in which potential markers of disease activity and damage are validated.</abstract><relatedItem type="host"><titleInfo><title>Medical Hypotheses</title></titleInfo><titleInfo type="abbreviated"><title>YMEHY</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1998</dateIssued></originInfo><identifier type="ISSN">0306-9877</identifier><identifier type="PII">S0306-9877(00)X0315-5</identifier><part><date>1998</date><detail type="volume"><number>50</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="issue-pages"><start>457</start><end>542</end></extent><extent unit="pages"><start>483</start><end>492</end></extent></part></relatedItem><identifier type="istex">1F22ACAE23135D33AFC33247C0574B536E66A427</identifier><identifier type="ark">ark:/67375/6H6-XK3BNRK0-3</identifier><identifier type="DOI">10.1016/S0306-9877(98)90268-7</identifier><identifier type="PII">S0306-9877(98)90268-7</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-XK3BNRK0-3/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001951 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001951 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1F22ACAE23135D33AFC33247C0574B536E66A427
|texte= Standardized assessment of disease status in patients with primary Sjögren's syndrome: the foundation for creating criteria for disease activity and damage?
}}
| This area was generated with Dilib version V0.6.33. |  |